17116-26-6Relevant articles and documents
Deposition of Ag and Ag-Au nanocrystalline films with tunable conductivity at the water-toluene interface
Stansfield, Gemma L.,Johnston, Helena M.,Baxter, Sean N.,Thomas, P. John
, p. 6225 - 6230 (2018)
Thin films of Au, Ag and Ag-Au alloy nanocrystals extending to areas of several square centimetres are obtained by deposition at the interface of water and toluene. Toluene containing chlorotris(triphenylphosphine)silver(i) and/or chlorotriphenylphosphine
New Structural Motifs Resulting from Internal Constraints in Chelating Bis(NHC) Ligands: A Dinuclear Ruthenium(II) Complex Featuring an η2-Arene Binding Mode and a Remarkable New Tetrameric Silver(I) Halide Form
Simpson, Peter V.,Brown, David H.,Skelton, Brian W.,White, Allan H.,Baker, Murray V.
, p. 2508 - 2514 (2015)
A novel dinuclear ruthenium(II) complex containing two ortho-xylylene-linked bis(NHC) ligands (NHC = N-heterocyclic carbene) has been synthesized via transmetalation from a silver-NHC complex. Each ruthenium atom in the dinuclear complex is chelated through the two carbene carbon atoms and, unusually, an η2-bound xylylene ring, two separate bis(NHC) units being linked by a Ru(μ-Cl)3Ru core. The same bis(NHC) ligand has yielded a neutral tetranuclear 4:2 AgBr:bis(NHC) complex, where ligand steric constraints seemingly inhibit formation of structures derivative of the more familiar "cubane" or "step" forms, resulting in an interesting new structural type. (Chemical Equation Presented).
USE OF SILVER(I) COMPLEXES AS ANTICANCER AGENTS
-
Paragraph 0225, (2017/09/08)
The present invention relates to the use of silver(I) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer.
